Choose a language and wait for the translated text.
MNC body, OPPI, has submitted formal representations to the CDSCO, seeking a US FDA-style, time-bound review of new drug applications. The lobby may revise its key demand of granting regulatory data production from 10 years to six years, in line with the protection period recently introduced by China.
Pharma multinationals seek time-bound review of IND applications; may settle for six-year data exclusivity | PharmaVoice